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Abstract Real-time interaction analysis, using the BIAcore bi-
osensor, of rabbit muscle FBPase^aldolase complex revealed
apparent binding constant [KAapp] values of about 4.4U108
M31. The stability of the complex was down-regulated by the
glycolytic intermediates dihydroxyacetone phosphate and fruc-
tose 6-phosphate, and by the regulator of glycolysis and glyco-
neogenesis ^ fructose 2,6-bisphosphate. FBPase in a complex
with aldolase was entirely insensitive to inhibition by physiolog-
ical concentrations of AMP (I0:5 was 1.35 mM) and the coop-
erativity of the inhibition was not observed. The existence of an
FBPase^aldolase complex that is insensitive to AMP inhibition
explains the possibility of glycogen synthesis from carbohydrate
precursors in vertebrates’ myocytes.
0 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The conversion of carbohydrate precursors into glucose
(gluconeogenesis) is necessary to maintain the required level
of blood glucose in mammals. Gluconeogenic activity occurs
mainly in liver and kidney. However, numerous studies have
shown that skeletal muscles, although unable to synthesize
and release glucose to blood, can synthesize glycogen from
carbohydrate precursors (glyconeogenesis) [1^3].
Fructose 1,6-bisphosphatase (FBPase) [EC 3.1.3.11] is the
key enzyme of gluconeogenesis and glyconeogenesis. The en-
zyme catalyzes hydrolysis of fructose 1,6-bisphosphate (F1,6-
P2) to fructose 6-phosphate (F6-P) and inorganic phosphate in
the presence of divalent metal ions (Mg2þ, Mn2þ, Co2þ and
Zn2þ) [4,5]. Mammalian FBPases are activated by monovalent
cations [4^6], inhibited competitively by fructose 2,6-bisphos-
phate (F2,6-P2) and allosterically by AMP [4,5,7^9]. A syner-
gistic e¡ect of both inhibitors on FBPase has also been re-
ported [8,10].
Liver and muscle isozymes have been found in mammalian
tissues [5,11]. The basic di¡erence between the liver and the
muscle FBPase concerns their sensitivity to AMP inhibition.
I0:5 for AMP for the muscle isozyme is about 0.1 WM and this
value is 50^100 times lower than the corresponding value
determined for the liver isozyme [5,12^15]. Taking into ac-
count that the AMP level in muscle cell is within the range
of 20^30 WM and F2,6-P2 is ca. 1^2.5 WM, the muscle FBPase
should be almost completely inhibited in vivo [10]. This raises
the question of how muscle FBPase may function in vivo,
and, following that, how glyconeogenesis can proceed in my-
ocytes.
Previously we have reported that muscle aldolase decreases
sensitivity of muscle FBPase to AMP inhibition; in the pres-
ence of 10 WM aldolase, I0:5 for AMP for muscle FBPase was
increased 10-fold [13].
Employing the new approach to aldolase^FBPase complex
activity measurement, we demonstrate that muscle FBPase is
almost completely desensitized by muscle aldolase to AMP
inhibition. We also present evidence that the aldolase^FBPase
complex concentration is down-regulated by low molecular
weight e¡ectors.
2. Materials and methods
Phosphocellulose P-11 was purchased from Whatman (Maidstone,
England), ethanolamine was from Merck (Germany), and BIAcore
sensor chips CM5 were from Biacore AB (Uppsala, Sweden). Other
reagents were from Sigma (St. Louis, MO, USA).
All the chemicals used were of analytical grade.
2.1. Enzyme puri¢cation and activity determination
Rabbit muscle aldolase and FBPase were puri¢ed according to
Penhoet et al. [16] and Rakus et al. [17], respectively. The activities
of aldolase and FBPase were determined as described by Racker
(modi¢ed) [18], and Rakus and Dzugaj [17], respectively.
Spectrophotometric measurements were performed with an HP
8452A diode array spectrophotometer. All kinetic calculations were
performed using Microsoft Excel 2000 and GraFit 4 programs [19].
2.2. The activity of FBPase^aldolase complex
To determine the activity of FBPase^aldolase complex in the pres-
ence of various concentrations of AMP and F2,6-P2 a great excess of
FBPase over aldolase (1000 times) and a physiological concentration
of dihydroxyacetone phosphate (DHAP) were used (80 WM DHAP
was added to the reaction mixture).
To check the e¡ect of DHAP on the rate of F6-P synthesis by
aldolase^FBPase complex, various concentrations of DHAP (0^1
mM) were used.
The standard assay medium contained: 0.1 Wg/ml aldolase, 100 Wg/
ml FBPase, 20 mM Tris, 0.25 mM EDTA, 1.25 mM MgCl2, 100 mM
KCl, 10% polyethylene glycol (PEG 8 000), 0.5 mM nicotinamide
adenine dinucleotide phosphate, 50 U/ml of glucose 6-phosphate de-
hydrogenase, 50 U/ml of glucose 6-phosphate isomerase, 50 U/ml of
triose 3-phosphate isomerase and 0.08 mM DHAP; pH 7.5, T=37‡C.
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2.3. Real-time interaction analysis by BIAcore
The binding of aldolase to immobilized FBPase was measured by
using BIAcore 1000 (Biacore AB, Uppsala, Sweden). The sensor chips
CM5 with carboxymethylated dextran matrix were used throughout
all experiments. Immobilization of rabbit muscle FBPase was carried
out using the standard EDC/NHS chemical procedure for activation
of a working channel. A 15 Wl solution of FBPase (0.2 mg/ml in 10
mM acetate bu¡er, pH 6.0, £ow rate 5 Wl/min) was injected over the
activated sensor surface, followed by a 50-Wl solution of 1 M ethanol-
amine to deactivate the unreacted NHS-esters. The chip was equili-
brated with the running bu¡er (5 mM HEPES, 0.05 mM EDTA, 50
mM KCl, pH 7.4, T=25‡C) until a stable baseline was obtained. All
binding experiments were carried out at 25‡C with a constant £ow
rate of 5 Wl/min in the running bu¡er, unless otherwise speci¢ed.
To determine the a⁄nity of aldolase to FBPase, 25 Wl aliquots of
various concentrations of aldolase (0.1^0.25 mg/ml in running bu¡er)
were injected over FBPase-immobilized sensor chip (association
phase), followed by a 10-min washing with the running bu¡er (disso-
ciation phase). The sensor surface was then regenerated by a 3-min
injection with 150 Wl of 10 mM HCl to remove the aldolase.
To check the in£uence of low molecular e¡ectors (AMP, DHAP,
F6-P, F2,6-P2) on the a⁄nity of aldolase to FBPase, the running
bu¡er was supplemented with appropriate concentrations of the e¡ec-
tors.
The analysis for the dissociation and association rate constants was
performed by the BIAevaluation 3.1 software supplied by the manu-
facturer.
3. Results
Several binding models were used to ¢t the results of real-
time interaction data between rabbit muscle aldolase and rab-
bit muscle FBPase. The best-¢tted model describing the inter-
action accounts for the existence of one binding site on the
surface of the FBPase molecule and two conformational states
of the complex. A globally ¢tted apparent binding constant
KAapp = (ka1/kd1)/(k2/k3) (where ka1, kd1, k2 and k3 are, re-
spectively, the ¢rst association and the ¢rst dissociation rate
constants, and the rate constants of transformation between
two conformational states of the complex) revealed that aldo-
lase interacts with FBPase with KAapp within the range of
4.4U108 to 6.15U108 M31 (Fig. 1a). Calculated, the associa-
tion constant (KA = (ka1/kd1)W2.6U106 M31) is much higher
than that reported previously: KAW1.15U105 M31 [13]. It
can be explained, at least partially, by lower salt concentration
in the binding medium used in this study (350 mM KCl), as
opposed to 150 mM KCl used in our previous report.
The stability of the aldolase^FBPase complex was almost
insensitive to the physiological concentration (20 WM) of
AMP (data not presented) and even a 100 WM concentration
of AMP decreased KAapp only about 20 times (Fig. 1b and
Table 1). A stronger destabilization of the complex was ob-
served in the presence of F2,6-P2, F6-P and DHAP (Fig. 1b
and Table 1). A two-fold higher than physiological, 5 WM
concentration of F2,6-P2 caused almost a 60-fold decrease
of the a⁄nity of aldolase to FBPase (Fig. 1b and Table 1).
The in£uence of DHAP on the aldolase^FBPase complex was
even stronger than the e¡ect of F2,6-P2, and the KAapp value
Fig. 1. a: The analysis of FBPase interactions with various concen-
trations of aldolase (solid line, 1.56 WM; dashed line, 1.25 WM; dot-
ted line, 0.625 WM) by surface plasmon resonance. KAapp values
were calculated using BIAevaluation 3.1 software from Biacore.
Each KAapp value represents the mean of triplicate determinations.
b: The in£uence of low molecular e¡ectors (AMP, DHAP, F6-P,
F2,6-P2) on the a⁄nity of aldolase (1.56 WM) to FBPase.
Table 1
Kinetic data on the binding of aldolase (1.56 WM) to FBPase, as measured by surface plasmon resonance ^ the in£uence of low molecular
weight e¡ectors
E¡ector ka1 [M31 s31] kd1 [s31] KA [M31] k2 [s31] k3 [s31] KAapp [M31]
In the absence of e¡ectors 1.61U104 6.26U1033 2.57U106 1.96U1033 1.13U1035 4.4U108
S.E.M. 25 S.E.M. 4.51U1035 S.E.M. 4.8U1035 S.E.M. 1.3U1034
AMP-100 WM 1.98U104 7.61U1033 2.60U106 3.22U1033 4.47U1034 1.9U107
S.E.M. 45 S.E.M. 4.86U1035 S.E.M. 9.57U1035 S.E.M. 1.23U1034
F6-P-200 WM 2.01U104 1.46U1032 1.38U106 1.17U1032 3.02U1033 7.8 U106
S.E.M. 166 S.E.M. 3.86U1034 S.E.M. 5.65U1034 S.E.M. 4.02U1035
F2,6-P2-5 WM 2.78U103 1.18U1032 2.36U105 8.45U1033 2.63U1033 7.5 U106
S.E.M. 147 S.E.M. 1.59U1034 S.E.M. 2.46U1034 S.E.M. 9.59U1035
DHAP-20 WM 3.54U104 4.81U1032 7.36U105 4.22U1033 6.98U1034 4.5 U106
S.E.M. 876 S.E.M. 1.27U1033 S.E.M. 1.23U1034 S.E.M. 4.69U1035
DHAP-40 WM 1.6U104 4.25U1032 3.76U105 9.17U1033 9.9U1034 3.5U106
S.E.M. 112 S.E.M. 3.72U1034 S.E.M. 7.67U1035 S.E.M. 1.12U1035
Each KAapp value represents the mean and standard error (S.E.M.) of triplicate determinations.
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determined in the presence of 40 WM DHAP was ca. 125 times
lower than KAapp determined in the absence of DHAP.
The F6-P concentration reported for a resting rabbit muscle
[20] reduced the KAapp for aldolase^FBPase complex more
than 50 times compared to KAapp for aldolase^FBPase in
the absence of e¡ectors (Fig. 1b and Table 1).
A standard assay for determination of FBPase activity in a
complex with aldolase was described by Rakus and Dzugaj
[13] as a development of the method of Morikofer-Zwez [21].
In that method a great excess of aldolase over FBPase (more
than 100 times) and high concentration of DHAP (0.5 mM)
were used. However, the data on the e¡ect of DHAP on
FBPase^aldolase complex stability suggest that this com-
pound strongly destabilizes the complex. This ¢nding explains
why Rakus and Dzugaj [13] could observe only partial desen-
sitization of FBPase by aldolase to AMP inhibition. It is
presumed that under the assay conditions used in our previous
report only a small part of FBPase molecules (ca. 1%) could
interact with aldolase. In the present paper we used a great
excess of FBPase over aldolase (1000 times) and a physiolog-
ical concentration of DHAP (Fig. 2). Under such conditions
more than 95% of aldolase should be saturated with FBPase
during the reaction.
The response of FBPase^aldolase complex activity to the
increasing concentration of DHAP was biphasic (solid line,
Fig. 3a). The rate of the reaction was linear up to 200 WM
concentration of added DHAP (dashed line) and the second
phase of the curve describing the dependence of FBPase ve-
locity on DHAP concentration was hyperbolic (dotted line).
FBPase in a complex with aldolase was inhibited by AMP,
with I0:5 ca. 1.35 mM and without any positive cooperativity
(Fig. 3b). Contrary to the inhibition of rabbit muscle FBPase
in the absence of aldolase, we could not observe any signi¢-
cant inhibition of the complex under AMP concentrations
below 100 WM (Fig. 3b, inset).
The inhibition of FBPase^aldolase complex by F2,6-P2 was
negatively cooperative (n was 0.65), and the concentration of
F2,6-P2 which caused a two-fold inhibition of the complex
was ca. 346 WM (Fig. 3c).
4. Discussion
The glycolytic and glyconeogenic enzymes have been con-
sidered as soluble constituents of the cell. However, many
studies indicate that glycolytic enzymes are reversibly associ-
ated with cellular structures and this association alters their
properties [22].
On the other hand, only little information is available on
the regulation and spatial organization of the enzymes of
glyconeogenesis. [13,23]. The basic problem of muscle glyco-
neogenesis is the apparent inactivity of muscle FBPase iso-
zyme under physiological concentrations of AMP. Recently,
we have shown that rabbit muscle FBPase is partially desen-
sitized to AMP inhibition by muscle aldolase [13]. By now we
have presented evidence that muscle FBPase in a complex
with muscle aldolase is practically completely insensitive to
AMP inhibition. In the presence of 20 mM AMP (about
1000 times higher than physiological concentration) only a
¢ve-fold inhibition of FBPase^aldolase complex was observed.
The destabilization of aldolase^FBPase complex by DHAP,
F6-P2 and F2,6-P2, which interact with active sites of aldolase
Fig. 2. In the presence of an excess of FBPase, the synthesis of
F1,6-P2 is practically catalyzed only by aldolase bound with
FBPase. Synthesized F1,6-P2 is targeted directly to FBPase, which
catalyzes its hydrolysis to F6-P.
Fig. 3. a: The biphasic response of FBPase^aldolase complex activ-
ity on DHAP concentration (solid line). The rate of the reaction is
linear up to 200 WM concentration of added DHAP (dashed line)
and the second phase of the curve describing the dependence of
FBPase velocity on DHAP concentration is hyperbolic (dotted line).
b: The inhibition of aldolase^FBPase complex by AMP. In the in-
set, the inhibition of muscle FBPase in a complex with aldolase (sol-
id line, empty circles) and muscle FBPase in the absence of aldolase
(dashed line, full circles) are presented. c: The inhibition of
FBPase^aldolase complex by F2,6-P2.
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and FBPase, was shown in the binding experiments (Fig. 1b
and Table 1).
F2,6-P2 is a competitive inhibitor of mammalian FBPases
with inhibitory constant (Ki) below 1 WM [7,8,10,14,17]. In the
presence of aldolase, the apparent Ki was about 350 WM. On
the other hand, F2,6-P2 signi¢cantly decreased the a⁄nity of
FBPase to aldolase: in the presence of 5 WM F2,6-P2, the
binding constant for a complex of aldolase^FBPase was low-
ered about 60 times. The similarity of the e¡ects of AMP and
F2,6-P2 on the kinetics and binding properties of the complex
strongly suggests a similar mechanism of the inhibition. Both
AMP and F2,6-P2 may interact with the active site of FBPase,
destabilizing the aldolase^FBPase complex. Thus, AMP and
F2,6-P2 decrease the concentration of the complex and, as a
result, they can inhibit FBPase activity in a classic manner.
The binding of DHAP to aldolase resulted in a dramatic
decrease of aldolase a⁄nity to FBPase ^ KAapp was reduced
more than 100 times. The dependence of the complex activity
versus increasing DHAP concentration was biphasic (Fig. 3a).
Supposedly, the ¢rst phase of the curve represents the state in
which almost all aldolase molecules were bound to FBPase.
The activity reported during the second phase of the curve,
under high concentrations of DHAP, seems to re£ect the ac-
tivity mainly of an unbound form of aldolase.
It is possible that within the complex the active sites of
FBPase are in close vicinity to active sites of aldolase. This
would enable a direct transfer, by channeling or restricted free
di¡usion mechanism, of F1,6-P2 from aldolase to FBPase.
The synthesis of glycogen from lactate in myocytes takes
place during recovery from exercise [2,24]. The concentrations
of DHAP, F6-P and F2,6-P2 in resting striated muscle cells
are, respectively, about 25^166 WM, 100^200 WM and below
1 WM [20,25]. After stimulation of muscle contraction the
concentration of these compounds immediately increases
two to four times in the ¢rst 10 s of stimulation [20]. Thus,
DHAP and F6-P might be the negative regulators of glyco-
neogenesis. F2,6-P2 is a commonly known inhibitor of
FBPase [7,8] ; however, its role in the regulation of glycogen
synthesis from lactate may be more complex. Supposedly,
F2,6-P2 inhibits glyconeogenesis not only by simple compet-
itive inhibition of FBPase but also by the destabilization of
the glyconeogenic complex aldolase^FBPase.
To conclude, the results presented in our report demon-
strate that muscle FBPase bound with aldolase is entirely
desensitized to AMP inhibition, which enables glycogen syn-
thesis from carbohydrate precursors in myocytes. The stability
of aldolase^FBPase complex is down-regulated by DHAP,
F6-P and F2,6-P2 ^ the compounds whose concentration in-
creases signi¢cantly and immediately during physical exercise.
Since DHAP, F2,6-P2 and F6-P bind to the active sites of the
enzymes, channeling or a restricted free di¡usion mechanism
of F1,6-P2 transfer from aldolase to FBPase may be expected.
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